
Jagsonpal Pharmaceuticals Ltd is Rated Sell
2026-03-20 10:10:03Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd Sees Mixed Technical Signals Amid Price Momentum Shift
2026-03-11 08:00:17Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a 4.24% gain on the day, the stock’s overall momentum and technical indicators suggest a cautious outlook, with a recent downgrade from Hold to Sell by MarketsMOJO underscoring the evolving market sentiment.
Read full news article
Jagsonpal Pharmaceuticals Ltd is Rated Sell
2026-03-09 10:10:18Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd is Rated Sell
2026-03-08 10:10:14Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd Valuation Shifts Signal Growing Price Caution
2026-03-04 08:00:07Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, reflecting changing market perceptions amid broader sector volatility. Despite robust operational metrics, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of price attractiveness relative to peers and historical averages.
Read full news article
Jagsonpal Pharmaceuticals Ltd is Rated Sell
2026-02-25 10:10:25Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd is Rated Sell
2026-02-14 10:10:18Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Change
2026-02-09 08:00:13Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects evolving market perceptions and impacts the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.
Read full news article
Jagsonpal Pharmaceuticals Ltd is Rated Sell
2026-02-03 10:10:04Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 February 2026, providing investors with the most recent insights into the company’s performance and outlook.
Read full news articleAnnouncement Under Regulation 30 Of Sebi LODR
13-Mar-2026 | Source : BSEPlease find attached disclosure under Regulation 30 of SEBI (LODR) Regulations 2015
Board Meeting Outcome for Outcome Of Board Meeting
12-Mar-2026 | Source : BSEPlease find attached outcome of meeting held on March 12 2026 for consideration of buy back of equity shares.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
12-Mar-2026 | Source : BSEPlease release on announcement of buy back of Equity shares of Company
Corporate Actions
No Upcoming Board Meetings
Jagsonpal Pharmaceuticals Ltd has declared 125% dividend, ex-date: 12 Sep 25
Jagsonpal Pharmaceuticals Ltd has announced 2:5 stock split, ex-date: 08 Jan 25
No Bonus history available
No Rights history available






